HEADER TRANSPORT PROTEIN 17-JUN-13 4L8U TITLE X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH 9 AMINO CAMPTOTHECIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: SERUM ALBUMIN; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: UNP RESIDUES 25-609 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606 KEYWDS PLASMA PROTEIN, ONCOLOGY DRUGS, PROTEIN DRUG COMPLEX, TRANSPORT KEYWDS 2 PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR Z.WANG,J.X.HO,J.RUBLE,J.P.ROSE,D.C.CARTER REVDAT 4 15-NOV-17 4L8U 1 REMARK REVDAT 3 19-FEB-14 4L8U 1 REMARK REVDAT 2 23-OCT-13 4L8U 1 JRNL REVDAT 1 24-JUL-13 4L8U 0 JRNL AUTH Z.M.WANG,J.X.HO,J.R.RUBLE,J.ROSE,F.RUKER,M.ELLENBURG, JRNL AUTH 2 R.MURPHY,J.CLICK,E.SOISTMAN,L.WILKERSON,D.C.CARTER JRNL TITL STRUCTURAL STUDIES OF SEVERAL CLINICALLY IMPORTANT ONCOLOGY JRNL TITL 2 DRUGS IN COMPLEX WITH HUMAN SERUM ALBUMIN. JRNL REF BIOCHIM.BIOPHYS.ACTA V.1830 5356 2013 JRNL REFN ISSN 0006-3002 JRNL PMID 23838380 JRNL DOI 10.1016/J.BBAGEN.2013.06.032 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH D.C.CARTER REMARK 1 TITL CRYSTALLOGRAPHIC SURVEY OF ALBUMIN DRUG INTERACTION AND REMARK 1 TITL 2 PRELIMINARY APPLICATIONS IN CANCER CHEMOTHERAPY REMARK 1 REF BURGERS MEDICINAL CHEMISTRY 437 2010 REMARK 1 REF 2 DRUG DESIGN AND DEVELOPMENT, REMARK 1 REF 3 7TH EDITION REMARK 1 PUBL JOHN WILEY & SONS REMARK 1 REFN REMARK 1 DOI 10.1002/0471266949 REMARK 1 REFERENCE 2 REMARK 1 AUTH D.C.CARTER,J.X.HO REMARK 1 TITL STRUCTURE OF SERUM ALBUMIN REMARK 1 REF ADV.PROTEIN CHEM. V. 45 153 1994 REMARK 1 REFN ISSN 0065-3233 REMARK 1 REFERENCE 3 REMARK 1 AUTH D.C.CARTER,B.CHANG,J.X.HO,K.KEELING,Z.KRISHNASAMI REMARK 1 TITL PRELIMINARY CRYSTALLOGRAPHIC STUDIES OF FOUR CRYSTAL FORMS REMARK 1 TITL 2 OF SERUM ALBUMIN. REMARK 1 REF EUR.J.BIOCHEM. V. 226 1049 1994 REMARK 1 REFN ISSN 0014-2956 REMARK 1 PMID 7813459 REMARK 1 REFERENCE 4 REMARK 1 AUTH X.M.HO,D.C.CARTER REMARK 1 TITL ERRATUM. ATOMIC STRUCTURE AND CHEMISTRY OF HUMAN SERUM REMARK 1 TITL 2 ALBUMIN REMARK 1 REF NATURE V. 364 362 1993 REMARK 1 REFN ISSN 0028-0836 REMARK 1 REFERENCE 5 REMARK 1 AUTH X.M.HE,D.C.CARTER REMARK 1 TITL ATOMIC STRUCTURE AND CHEMISTRY OF HUMAN SERUM ALBUMIN. REMARK 1 REF NATURE V. 358 209 1992 REMARK 1 REFN ISSN 0028-0836 REMARK 1 PMID 1630489 REMARK 1 DOI 10.1038/358209A0 REMARK 1 REFERENCE 6 REMARK 1 AUTH D.C.CARTER,X.M.HO REMARK 1 TITL STRUCTURE OF HUMAN SERUM ALBUMIN REMARK 1 REF SCIENCE V. 249 302 1990 REMARK 1 REFN ISSN 0036-8075 REMARK 1 REFERENCE 7 REMARK 1 AUTH D.C.CARTER,X.M.HE,S.H.MUNSON,P.D.TWIGG,K.M.GERNERT, REMARK 1 AUTH 2 M.B.BROOM,T.Y.MILLER REMARK 1 TITL THREE-DIMENSIONAL STRUCTURE OF HUMAN SERUM ALBUMIN. REMARK 1 REF SCIENCE V. 244 1195 1989 REMARK 1 REFN ISSN 0036-8075 REMARK 1 PMID 2727704 REMARK 2 REMARK 2 RESOLUTION. 2.01 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.8.2_1309 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.01 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.71 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 89.7 REMARK 3 NUMBER OF REFLECTIONS : 38472 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.200 REMARK 3 R VALUE (WORKING SET) : 0.198 REMARK 3 FREE R VALUE : 0.243 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.980 REMARK 3 FREE R VALUE TEST SET COUNT : 1915 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 45.7257 - 4.8393 0.84 2564 136 0.1852 0.2230 REMARK 3 2 4.8393 - 3.8417 0.88 2594 138 0.1646 0.1958 REMARK 3 3 3.8417 - 3.3563 0.90 2620 145 0.1927 0.2295 REMARK 3 4 3.3563 - 3.0495 0.91 2659 139 0.2057 0.2327 REMARK 3 5 3.0495 - 2.8309 0.92 2665 138 0.2132 0.2592 REMARK 3 6 2.8309 - 2.6641 0.91 2657 136 0.2143 0.2780 REMARK 3 7 2.6641 - 2.5306 0.94 2698 136 0.2159 0.2985 REMARK 3 8 2.5306 - 2.4205 0.93 2691 145 0.2118 0.2636 REMARK 3 9 2.4205 - 2.3273 0.92 2680 140 0.2133 0.2922 REMARK 3 10 2.3273 - 2.2470 0.95 2708 141 0.2093 0.2405 REMARK 3 11 2.2470 - 2.1768 0.92 2706 135 0.2122 0.2657 REMARK 3 12 2.1768 - 2.1145 0.96 2721 145 0.2191 0.2826 REMARK 3 13 2.1145 - 2.0589 0.85 2483 129 0.2116 0.2979 REMARK 3 14 2.0589 - 2.0100 0.74 2111 112 0.2018 0.2409 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.230 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 24.370 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.11 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.008 4849 REMARK 3 ANGLE : 1.185 6498 REMARK 3 CHIRALITY : 0.079 709 REMARK 3 PLANARITY : 0.005 838 REMARK 3 DIHEDRAL : 15.657 1855 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4L8U COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-JUL-13. REMARK 100 THE DEPOSITION ID IS D_1000080326. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-JAN-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.3 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 38473 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.010 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.7 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.04800 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.01 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.08 REMARK 200 COMPLETENESS FOR SHELL (%) : 75.3 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.29700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MERLOT REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.56 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 3350, POTASSIUM PHOSPHATE, PH 7.5, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K. CRYSTALS OF THE REMARK 280 COMPLEXES WERE OBTAINED BY STANDARD VAPOR EQUILIBRATION METHODS REMARK 280 WITH CONDITIONS OPTIMIZED BY SCREENS VARYING PROTEIN REMARK 280 CONCENTRATION, PH, DRUG MOLAR RATIOS, CENTERED ON THE ORIGINAL REMARK 280 CRYSTALLIZATION HIT USING PROTOCOLS DESCRIBED PREVIOUSLY FOR THE REMARK 280 MONOCLINIC [CARTER, ET AL., EUR. J. BIOCHEMISTRY (1994) 226: REMARK 280 1049-1052] AND TRICLINIC [SUGO, ET AL., PROTEIN ENG (1999) 12: REMARK 280 439-446] CRYSTAL FORMS. REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 91.96650 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 18.99950 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 91.96650 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 18.99950 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 1 REMARK 465 LEU A 585 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 907 O HOH A 934 1.82 REMARK 500 O HOH A 927 O HOH A 1008 1.89 REMARK 500 OE1 GLU A 167 O HOH A 1025 1.92 REMARK 500 OE1 GLU A 376 O HOH A 795 1.93 REMARK 500 O HOH A 886 O HOH A 1066 1.94 REMARK 500 O HOH A 1042 O HOH A 1060 1.94 REMARK 500 O HOH A 950 O HOH A 1000 1.95 REMARK 500 O HOH A 889 O HOH A 1024 1.95 REMARK 500 NZ LYS A 195 O HOH A 1015 1.98 REMARK 500 O HOH A 828 O HOH A 1065 2.00 REMARK 500 OE1 GLN A 397 O HOH A 1087 2.00 REMARK 500 O LYS A 573 O HOH A 786 2.02 REMARK 500 O HOH A 817 O HOH A 1016 2.02 REMARK 500 O HOH A 702 O HOH A 1011 2.03 REMARK 500 OE1 GLN A 196 O HOH A 1013 2.05 REMARK 500 O HOH A 875 O HOH A 1021 2.06 REMARK 500 NH1 ARG A 410 O HOH A 958 2.08 REMARK 500 O HOH A 999 O HOH A 1020 2.10 REMARK 500 O THR A 566 N GLU A 570 2.10 REMARK 500 O GLU A 520 O HOH A 913 2.10 REMARK 500 O HOH A 921 O HOH A 939 2.11 REMARK 500 O HOH A 820 O HOH A 986 2.11 REMARK 500 O HOH A 992 O HOH A 1024 2.11 REMARK 500 O HOH A 1076 O HOH A 1126 2.13 REMARK 500 O HOH A 1073 O HOH A 1086 2.14 REMARK 500 OE1 GLN A 459 O HOH A 908 2.15 REMARK 500 O HOH A 949 O HOH A 1123 2.16 REMARK 500 O HOH A 789 O HOH A 885 2.17 REMARK 500 O ARG A 114 O HOH A 788 2.17 REMARK 500 O HOH A 970 O HOH A 1048 2.18 REMARK 500 O HOH A 867 O HOH A 1063 2.19 REMARK 500 OG SER A 270 O HOH A 965 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 834 O HOH A 835 4545 2.05 REMARK 500 O HOH A 1082 O HOH A 1114 1545 2.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 CYS A 567 CB CYS A 567 SG -0.142 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 PRO A 96 C - N - CA ANGL. DEV. = -17.4 DEGREES REMARK 500 CYS A 567 CA - CB - SG ANGL. DEV. = 9.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 4 -94.36 158.23 REMARK 500 ASP A 56 105.65 -162.82 REMARK 500 ASN A 61 -2.60 70.25 REMARK 500 ASN A 130 84.80 -170.76 REMARK 500 ILE A 271 -57.52 -127.40 REMARK 500 VAL A 310 -43.98 -132.70 REMARK 500 ALA A 322 81.50 -166.14 REMARK 500 GLU A 479 178.11 -57.16 REMARK 500 ALA A 561 76.74 -179.86 REMARK 500 ASP A 562 -178.12 69.68 REMARK 500 ASP A 563 109.02 -52.09 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 601 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 602 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 603 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 604 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MYR A 605 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 9AZ A 606 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4L9K RELATED DB: PDB REMARK 900 RELATED ID: 4L9Q RELATED DB: PDB REMARK 900 RELATED ID: 4LA0 RELATED DB: PDB REMARK 900 RELATED ID: 4LB2 RELATED DB: PDB REMARK 900 RELATED ID: 4LB9 RELATED DB: PDB DBREF 4L8U A 1 585 UNP P02768 ALBU_HUMAN 25 609 SEQRES 1 A 585 ASP ALA HIS LYS SER GLU VAL ALA HIS ARG PHE LYS ASP SEQRES 2 A 585 LEU GLY GLU GLU ASN PHE LYS ALA LEU VAL LEU ILE ALA SEQRES 3 A 585 PHE ALA GLN TYR LEU GLN GLN CYS PRO PHE GLU ASP HIS SEQRES 4 A 585 VAL LYS LEU VAL ASN GLU VAL THR GLU PHE ALA LYS THR SEQRES 5 A 585 CYS VAL ALA ASP GLU SER ALA GLU ASN CYS ASP LYS SER SEQRES 6 A 585 LEU HIS THR LEU PHE GLY ASP LYS LEU CYS THR VAL ALA SEQRES 7 A 585 THR LEU ARG GLU THR TYR GLY GLU MET ALA ASP CYS CYS SEQRES 8 A 585 ALA LYS GLN GLU PRO GLU ARG ASN GLU CYS PHE LEU GLN SEQRES 9 A 585 HIS LYS ASP ASP ASN PRO ASN LEU PRO ARG LEU VAL ARG SEQRES 10 A 585 PRO GLU VAL ASP VAL MET CYS THR ALA PHE HIS ASP ASN SEQRES 11 A 585 GLU GLU THR PHE LEU LYS LYS TYR LEU TYR GLU ILE ALA SEQRES 12 A 585 ARG ARG HIS PRO TYR PHE TYR ALA PRO GLU LEU LEU PHE SEQRES 13 A 585 PHE ALA LYS ARG TYR LYS ALA ALA PHE THR GLU CYS CYS SEQRES 14 A 585 GLN ALA ALA ASP LYS ALA ALA CYS LEU LEU PRO LYS LEU SEQRES 15 A 585 ASP GLU LEU ARG ASP GLU GLY LYS ALA SER SER ALA LYS SEQRES 16 A 585 GLN ARG LEU LYS CYS ALA SER LEU GLN LYS PHE GLY GLU SEQRES 17 A 585 ARG ALA PHE LYS ALA TRP ALA VAL ALA ARG LEU SER GLN SEQRES 18 A 585 ARG PHE PRO LYS ALA GLU PHE ALA GLU VAL SER LYS LEU SEQRES 19 A 585 VAL THR ASP LEU THR LYS VAL HIS THR GLU CYS CYS HIS SEQRES 20 A 585 GLY ASP LEU LEU GLU CYS ALA ASP ASP ARG ALA ASP LEU SEQRES 21 A 585 ALA LYS TYR ILE CYS GLU ASN GLN ASP SER ILE SER SER SEQRES 22 A 585 LYS LEU LYS GLU CYS CYS GLU LYS PRO LEU LEU GLU LYS SEQRES 23 A 585 SER HIS CYS ILE ALA GLU VAL GLU ASN ASP GLU MET PRO SEQRES 24 A 585 ALA ASP LEU PRO SER LEU ALA ALA ASP PHE VAL GLU SER SEQRES 25 A 585 LYS ASP VAL CYS LYS ASN TYR ALA GLU ALA LYS ASP VAL SEQRES 26 A 585 PHE LEU GLY MET PHE LEU TYR GLU TYR ALA ARG ARG HIS SEQRES 27 A 585 PRO ASP TYR SER VAL VAL LEU LEU LEU ARG LEU ALA LYS SEQRES 28 A 585 THR TYR GLU THR THR LEU GLU LYS CYS CYS ALA ALA ALA SEQRES 29 A 585 ASP PRO HIS GLU CYS TYR ALA LYS VAL PHE ASP GLU PHE SEQRES 30 A 585 LYS PRO LEU VAL GLU GLU PRO GLN ASN LEU ILE LYS GLN SEQRES 31 A 585 ASN CYS GLU LEU PHE GLU GLN LEU GLY GLU TYR LYS PHE SEQRES 32 A 585 GLN ASN ALA LEU LEU VAL ARG TYR THR LYS LYS VAL PRO SEQRES 33 A 585 GLN VAL SER THR PRO THR LEU VAL GLU VAL SER ARG ASN SEQRES 34 A 585 LEU GLY LYS VAL GLY SER LYS CYS CYS LYS HIS PRO GLU SEQRES 35 A 585 ALA LYS ARG MET PRO CYS ALA GLU ASP TYR LEU SER VAL SEQRES 36 A 585 VAL LEU ASN GLN LEU CYS VAL LEU HIS GLU LYS THR PRO SEQRES 37 A 585 VAL SER ASP ARG VAL THR LYS CYS CYS THR GLU SER LEU SEQRES 38 A 585 VAL ASN ARG ARG PRO CYS PHE SER ALA LEU GLU VAL ASP SEQRES 39 A 585 GLU THR TYR VAL PRO LYS GLU PHE ASN ALA GLU THR PHE SEQRES 40 A 585 THR PHE HIS ALA ASP ILE CYS THR LEU SER GLU LYS GLU SEQRES 41 A 585 ARG GLN ILE LYS LYS GLN THR ALA LEU VAL GLU LEU VAL SEQRES 42 A 585 LYS HIS LYS PRO LYS ALA THR LYS GLU GLN LEU LYS ALA SEQRES 43 A 585 VAL MET ASP ASP PHE ALA ALA PHE VAL GLU LYS CYS CYS SEQRES 44 A 585 LYS ALA ASP ASP LYS GLU THR CYS PHE ALA GLU GLU GLY SEQRES 45 A 585 LYS LYS LEU VAL ALA ALA SER GLN ALA ALA LEU GLY LEU HET MYR A 601 16 HET MYR A 602 16 HET MYR A 603 16 HET MYR A 604 16 HET MYR A 605 16 HET 9AZ A 606 28 HETNAM MYR MYRISTIC ACID HETNAM 9AZ (2S)-2-[1-AMINO-8-(HYDROXYMETHYL)-9-OXO-9,11- HETNAM 2 9AZ DIHYDROINDOLIZINO[1,2-B]QUINOLIN-7-YL]-2- HETNAM 3 9AZ HYDROXYBUTANOIC ACID HETSYN 9AZ 9 AMINO CAMPTOTHECIN, OPEN FORM FORMUL 2 MYR 5(C14 H28 O2) FORMUL 7 9AZ C20 H19 N3 O5 FORMUL 8 HOH *428(H2 O) HELIX 1 1 SER A 5 GLY A 15 1 11 HELIX 2 2 GLY A 15 LEU A 31 1 17 HELIX 3 3 PRO A 35 ASP A 56 1 22 HELIX 4 4 SER A 65 CYS A 75 1 11 HELIX 5 5 THR A 79 GLY A 85 1 7 HELIX 6 6 GLU A 86 LYS A 93 5 8 HELIX 7 7 GLN A 94 HIS A 105 1 12 HELIX 8 8 GLU A 119 ASN A 130 1 12 HELIX 9 9 ASN A 130 HIS A 146 1 17 HELIX 10 10 TYR A 150 CYS A 169 1 20 HELIX 11 11 ASP A 173 PHE A 223 1 51 HELIX 12 12 GLU A 227 GLY A 248 1 22 HELIX 13 13 ASP A 249 ASN A 267 1 19 HELIX 14 14 GLN A 268 ILE A 271 5 4 HELIX 15 15 LEU A 275 LYS A 281 1 7 HELIX 16 16 PRO A 282 GLU A 292 1 11 HELIX 17 17 LEU A 305 VAL A 310 1 6 HELIX 18 18 ASP A 314 ALA A 322 1 9 HELIX 19 19 ALA A 322 ARG A 337 1 16 HELIX 20 20 SER A 342 CYS A 361 1 20 HELIX 21 21 ASP A 365 ALA A 371 1 7 HELIX 22 22 LYS A 372 VAL A 415 1 44 HELIX 23 23 SER A 419 CYS A 438 1 20 HELIX 24 24 PRO A 441 THR A 467 1 27 HELIX 25 25 SER A 470 GLU A 479 1 10 HELIX 26 26 SER A 480 ALA A 490 1 11 HELIX 27 27 ALA A 504 THR A 508 5 5 HELIX 28 28 HIS A 510 THR A 515 5 6 HELIX 29 29 SER A 517 LYS A 536 1 20 HELIX 30 30 THR A 540 LYS A 560 1 21 HELIX 31 31 GLU A 565 LEU A 583 1 19 SSBOND 1 CYS A 53 CYS A 62 1555 1555 2.04 SSBOND 2 CYS A 75 CYS A 91 1555 1555 2.05 SSBOND 3 CYS A 90 CYS A 101 1555 1555 2.03 SSBOND 4 CYS A 124 CYS A 169 1555 1555 2.05 SSBOND 5 CYS A 168 CYS A 177 1555 1555 2.04 SSBOND 6 CYS A 200 CYS A 246 1555 1555 2.04 SSBOND 7 CYS A 245 CYS A 253 1555 1555 2.02 SSBOND 8 CYS A 265 CYS A 279 1555 1555 2.03 SSBOND 9 CYS A 278 CYS A 289 1555 1555 2.04 SSBOND 10 CYS A 316 CYS A 361 1555 1555 2.03 SSBOND 11 CYS A 360 CYS A 369 1555 1555 2.06 SSBOND 12 CYS A 392 CYS A 438 1555 1555 2.04 SSBOND 13 CYS A 437 CYS A 448 1555 1555 2.04 SSBOND 14 CYS A 461 CYS A 477 1555 1555 2.02 SSBOND 15 CYS A 476 CYS A 487 1555 1555 2.03 SSBOND 16 CYS A 514 CYS A 559 1555 1555 2.04 SSBOND 17 CYS A 558 CYS A 567 1555 1555 2.02 SITE 1 AC1 7 VAL A 23 TYR A 150 ALA A 254 ARG A 257 SITE 2 AC1 7 LEU A 284 SER A 287 HOH A 787 SITE 1 AC2 7 SER A 342 VAL A 344 ARG A 348 LEU A 430 SITE 2 AC2 7 LEU A 453 ARG A 485 MYR A 603 SITE 1 AC3 9 ASN A 391 ARG A 410 TYR A 411 VAL A 418 SITE 2 AC3 9 LEU A 423 LEU A 460 PHE A 488 MYR A 602 SITE 3 AC3 9 HOH A1044 SITE 1 AC4 5 TYR A 401 LYS A 525 ALA A 528 LEU A 529 SITE 2 AC4 5 SER A 579 SITE 1 AC5 7 ALA A 210 ALA A 213 ASP A 324 LEU A 327 SITE 2 AC5 7 VAL A 482 HOH A1093 HOH A1116 SITE 1 AC6 12 LEU A 115 ARG A 117 ILE A 142 HIS A 146 SITE 2 AC6 12 PHE A 149 LEU A 182 ARG A 186 GLY A 189 SITE 3 AC6 12 SER A 193 HOH A 708 HOH A 730 HOH A 920 CRYST1 183.933 37.999 94.598 90.00 104.93 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.005437 0.000000 0.001450 0.00000 SCALE2 0.000000 0.026316 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010940 0.00000